DK3681885T3 - Tetrahydro-imidazo-quinolinsammensætninger som cbp/p300-inhibitorer - Google Patents

Tetrahydro-imidazo-quinolinsammensætninger som cbp/p300-inhibitorer Download PDF

Info

Publication number
DK3681885T3
DK3681885T3 DK18833127.6T DK18833127T DK3681885T3 DK 3681885 T3 DK3681885 T3 DK 3681885T3 DK 18833127 T DK18833127 T DK 18833127T DK 3681885 T3 DK3681885 T3 DK 3681885T3
Authority
DK
Denmark
Prior art keywords
cbp
imidazo
tetrahydro
inhibitors
quinoline compounds
Prior art date
Application number
DK18833127.6T
Other languages
English (en)
Inventor
Shawn E R Schiller
Torsten Herbertz
Hongbin Li
Bradford Graves
Steven Mischke
Angela V West
Anna Ericsson
Jennifer R Downing
Original Assignee
Forma Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forma Therapeutics Inc filed Critical Forma Therapeutics Inc
Application granted granted Critical
Publication of DK3681885T3 publication Critical patent/DK3681885T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
DK18833127.6T 2017-09-15 2018-09-14 Tetrahydro-imidazo-quinolinsammensætninger som cbp/p300-inhibitorer DK3681885T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762559436P 2017-09-15 2017-09-15
US201862692593P 2018-06-29 2018-06-29
PCT/US2018/051235 WO2019055877A1 (en) 2017-09-15 2018-09-14 TETRAHYDROIMIDAZO QUINOLINE COMPOSITIONS AS INHIBITORS OF CBP / P300

Publications (1)

Publication Number Publication Date
DK3681885T3 true DK3681885T3 (da) 2024-04-15

Family

ID=63714164

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18833127.6T DK3681885T3 (da) 2017-09-15 2018-09-14 Tetrahydro-imidazo-quinolinsammensætninger som cbp/p300-inhibitorer

Country Status (8)

Country Link
US (3) US11292791B2 (da)
EP (1) EP3681885B1 (da)
AU (1) AU2018334272B2 (da)
CA (1) CA3075880A1 (da)
DK (1) DK3681885T3 (da)
MA (1) MA50250A (da)
TW (2) TWI795440B (da)
WO (2) WO2019055869A1 (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019055869A1 (en) 2017-09-15 2019-03-21 Forma Therapeutics, Inc. TETRAHYDROIMIDAZO QUINOLINE COMPOSITIONS AS INHIBITORS OF CBP / P300
MX2020014303A (es) 2018-06-29 2021-03-25 Forma Therapeutics Inc Inhibición de la proteína de union a creb (cbp).
EP3587418B1 (en) * 2018-06-29 2021-09-01 Forma Therapeutics, Inc. Inhibitors of creb binding protein (cbp)
AU2020241709A1 (en) * 2019-03-15 2021-09-23 Forma Therapeutics, Inc. Compositions and methods for treating androgen receptor positive forms of cancer
WO2020190780A1 (en) * 2019-03-15 2020-09-24 Forma Therapeutics, Inc. Inhibiting cyclic amp-responsive element-binding protein (creb)
US11801243B2 (en) 2020-09-23 2023-10-31 Forma Therapeutics, Inc. Bromodomain inhibitors for androgen receptor-driven cancers
US11795168B2 (en) 2020-09-23 2023-10-24 Forma Therapeutics, Inc. Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP)
JPWO2022138944A1 (da) * 2020-12-25 2022-06-30

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4404207A (en) 1981-11-06 1983-09-13 Riker Laboratories, Inc. Antimicrobial 8-substituted benzo [IJ]quinolizines
AU1868195A (en) 1994-01-28 1995-08-15 Cell Therapeutics, Inc. Cell signaling inhibitors
US6011029A (en) 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
US6455564B1 (en) 1999-01-06 2002-09-24 Pharmacia & Upjohn Company Method of treating sexual disturbances
US7101869B2 (en) 1999-11-30 2006-09-05 Pfizer Inc. 2,4-diaminopyrimidine compounds useful as immunosuppressants
US7345051B2 (en) 2000-01-31 2008-03-18 Genaera Corporation Mucin synthesis inhibitors
US7122227B2 (en) 2000-11-20 2006-10-17 Merck Patent Gesellschaft Chiral photoisomerizable compounds
CA2463136A1 (en) 2001-10-17 2003-04-24 Raymond Andersen Ship 1 modulators
WO2003045929A1 (fr) 2001-11-26 2003-06-05 Takeda Chemical Industries, Ltd. Derive bicyclique, procede de production de ce derive et utilisation correspondante
HUP0203976A3 (en) 2002-11-15 2004-08-30 Sanofi Aventis Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them
TWI322012B (en) 2002-12-20 2010-03-21 Organon Nv Tetrahydroquinoline derivatives
IN2003CH00929A (da) 2003-11-13 2008-10-06
WO2005066162A1 (en) 2003-12-23 2005-07-21 Human Biomolecular Research Institute Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer
CA2562244A1 (en) 2004-04-07 2005-10-27 Takeda Pharmaceutical Company Limited Cyclic compounds
WO2005105814A1 (en) 2004-04-28 2005-11-10 Incyte Corporation Tetracyclic inhibitors of janus kinases
JP2009520038A (ja) 2005-12-19 2009-05-21 ジェネンテック・インコーポレーテッド ピリミジンキナーゼインヒビター
US20070203236A1 (en) 2006-01-11 2007-08-30 Smith Jeffrey W Novel antagonists of the human fatty acid synthase thioesterase
BRPI0713096A2 (pt) 2006-05-09 2012-10-16 Hemaquest Pharmaceuticals Inc métodos para tratar distúrbios sangüìneos
EP1878724A1 (en) 2006-07-15 2008-01-16 sanofi-aventis A regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles
CA2574531C (en) 2007-01-19 2016-10-25 The University Of British Columbia Hat acetylation promoters and uses of compositions thereof in promoting immunogenicity
US8476458B2 (en) 2007-06-21 2013-07-02 The Wistar Institute Methods and compositions for modulating P300/CBP activity
KR20100023907A (ko) 2007-06-26 2010-03-04 사노피-아벤티스 벤즈이미다졸 및 아자벤즈이미다졸의 위치선택적 구리 촉매화 합성
US8222417B2 (en) 2007-06-27 2012-07-17 Taisho Pharmaceutical Co., Ltd Compound having 11β-HSD1 inhibitory activity
TW200930369A (en) 2007-11-15 2009-07-16 Astrazeneca Ab Bis-(sulfonylamino) derivatives in therapy
AR072008A1 (es) 2008-06-13 2010-07-28 Merck & Co Inc Compuestos heterobiciclicos como agentes de inhibicion de quinasa p38
KR20110022672A (ko) 2008-06-16 2011-03-07 유니버시티 오브 테네시 리서치 파운데이션 암 치료용 화합물
JP5586585B2 (ja) 2009-03-27 2014-09-10 興和株式会社 縮合ピペリジン化合物及びこれを含有する医薬
WO2010118208A1 (en) 2009-04-09 2010-10-14 Exelixis, Inc. Benzoxazepin-4- (5h) -yl derivatives and their use to treat cancer
BRPI1014574A2 (pt) 2009-04-15 2015-08-25 Jw Pharmaceutical Corp Compostos inéditos de imitadores de ligação revesa, método para fabricar os mesmos e uso destes
WO2010138490A1 (en) 2009-05-26 2010-12-02 Exelixis, Inc. Benzoxazepines as inhibitors of mtor and methods of their use and manufacture
NZ596552A (en) 2009-05-26 2014-02-28 Exelixis Inc Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
US9005670B2 (en) 2010-01-05 2015-04-14 The Johns Hopkins University Use of histone acetyltransferase inhibitors as novel anti-cancer therapies
CA2791738C (en) 2010-03-01 2020-06-09 Gtx, Inc. Aryl imidazolyl compounds for the treatment of cancer
CA2800618C (en) 2010-05-26 2018-08-28 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
WO2012019093A1 (en) 2010-08-05 2012-02-09 Human Biomolecular Research Institute Synthetic compounds and methods to decrease nicotine self-administration
JP5937102B2 (ja) 2010-12-14 2016-06-22 エレクトロフォレティクス リミテッド カゼインキナーゼ１デルタ（ｃｋ１デルタ）阻害剤
US8765978B2 (en) 2010-12-16 2014-07-01 Transitions Optical, Inc. Method of making indeno-fused naphthol materials
CA2827392A1 (en) 2011-02-24 2012-08-30 Emory University Noggin blocking compositions for ossification and methods related thereto
TW201837023A (zh) 2011-07-01 2018-10-16 美商基利科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
WO2013148114A1 (en) 2012-03-30 2013-10-03 University Of Florida Research Foundation, Inc. P300/cbp inhibitors and methods of use
US9211333B2 (en) 2012-06-05 2015-12-15 Hong Kong Baptist University Anti-cancer agents synthesized based on miliusane compounds
US9593115B2 (en) 2012-09-21 2017-03-14 Advinus Therapeutics Ltd. Substituted fused tricyclic compounds, compositions, and medicinal applications thereof
RU2543485C2 (ru) 2013-02-26 2015-03-10 Андрей Александрович Иващенко Гетероциклические агонисты рецепторов желчных кислот tgr5, фармацевтическая композиция, способы их получения и применения
TWI527811B (zh) 2013-05-09 2016-04-01 吉李德科學股份有限公司 作爲溴結構域抑制劑的苯並咪唑衍生物
EP3010918B1 (en) 2013-06-21 2018-08-15 Zenith Epigenetics Ltd. Novel substituted bicyclic compounds as bromodomain inhibitors
EP3674300B1 (en) 2013-06-21 2022-10-12 Zenith Epigenetics Ltd. Novel bicyclic bromodomain inhibitors
RU2016105108A (ru) 2013-07-25 2017-08-30 Дана-Фарбер Кэнсер Инститьют, Инк. Ингибиторы факторов транскрипции и их применение
DE102013215912B3 (de) 2013-08-12 2015-02-26 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Farbneutral beschichteter kupferhaltiger Gegenstand, Verfahren zu dessen Herstellung sowie Verwendung einer entsprechenden farbneutralen Beschichtung
TW201605859A (zh) 2013-11-14 2016-02-16 必治妥美雅史谷比公司 作為酪蛋白激酶１δ／ε抑制劑之新穎經取代之吡唑并－哌
WO2015074081A1 (en) 2013-11-18 2015-05-21 Bair Kenneth W Benzopiperazine compositions as bet bromodomain inhibitors
CN110627770A (zh) 2013-11-18 2019-12-31 福马疗法公司 作为bet溴域抑制剂的四氢喹啉组成物
EP3193866A1 (en) 2014-09-19 2017-07-26 Genentech, Inc. Use of cbp/ep300 and bet inhibitors for treatment of cancer
CN107531690B (zh) * 2014-11-27 2020-11-06 基因泰克公司 用作CBP和/或EP300抑制剂的4,5,6,7-四氢-1H-吡唑并[4,3-c]吡啶-3-胺化合物
WO2016110821A1 (en) 2015-01-08 2016-07-14 Advinus Therapeutics Limited Bicyclic compounds, compositions and medicinal applications thereof
WO2016128908A1 (en) 2015-02-12 2016-08-18 Advinus Therapeutics Limited Bicyclic compounds, compositions and medicinal applications thereof
GB201506660D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
GB201506658D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
WO2017197056A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Bromodomain targeting degronimers for target protein degradation
US11883381B2 (en) 2016-05-12 2024-01-30 The Regents Of The University Of Michigan ASH1L inhibitors and methods of treatment therewith
JP7160688B2 (ja) 2016-05-24 2022-10-25 ジェネンテック， インコーポレイテッド Ｃｂｐ／ｅｐ３００の複素環式インヒビターおよびがんの処置におけるそれらの使用
GB201617630D0 (en) 2016-10-18 2016-11-30 Cellcentric Ltd Pharmaceutical compounds
GB201617627D0 (en) 2016-10-18 2016-11-30 Cellcentric Ltd Pharmaceutical compounds
WO2019055869A1 (en) 2017-09-15 2019-03-21 Forma Therapeutics, Inc. TETRAHYDROIMIDAZO QUINOLINE COMPOSITIONS AS INHIBITORS OF CBP / P300

Also Published As

Publication number Publication date
AU2018334272B2 (en) 2023-06-15
CA3075880A1 (en) 2019-03-21
AU2018334272A1 (en) 2020-04-16
MA50250A (fr) 2020-07-22
US20240150349A1 (en) 2024-05-09
EP3681885A1 (en) 2020-07-22
US20200216445A1 (en) 2020-07-09
WO2019055869A1 (en) 2019-03-21
EP3681885B1 (en) 2024-02-28
TW201920169A (zh) 2019-06-01
US11292791B2 (en) 2022-04-05
US11787803B2 (en) 2023-10-17
TW202340191A (zh) 2023-10-16
US20220169647A1 (en) 2022-06-02
TWI795440B (zh) 2023-03-11
WO2019055877A1 (en) 2019-03-21

Similar Documents

Publication Publication Date Title
DK3442980T3 (da) Heterocykliske forbindelser som ret-kinase-hæmmere
DK3873903T3 (da) Substituerede 6-azabenzimidazolforbindelser som hpk1-hæmmere
DK3788040T3 (da) Pyridazinoner som parp7-inhibitorer
DK3697785T3 (da) Imidazo-pyridine forbindelser som pad-inhibitorer
DK3656769T3 (da) Aryl-phosphor-oxygen-forbindelse som egfr-kinase-inhibitor
DK3277677T3 (da) 1-cyano-pyrrolidinforbindelser som usp30-hæmmere
DK3436461T3 (da) Pyrrolotriazinforbindelser som tam-inhibitorer
DK3371190T3 (da) Heterocykliske forbindelser som pi3k-gamma-inhibitorer
DK3472167T3 (da) Heterocykliske forbindelser som immunomodulatorer
DK3377488T3 (da) Heterocykliske forbindelser som immunomodulatorer
DK3442947T3 (da) Aminsubstituerede aryl- eller heteroarylforbindelser som ehmt1- og ehmt2-hæmmere
DK3728252T3 (da) 4-azaindolforbindelser
DK3298002T3 (da) Heterocykliske amider som kinasehæmmere
DK3303348T3 (da) Naphthyridinforbindelser som JAK-kinaseinhibitorer
DK3390395T3 (da) Forbindelser, der kan anvendes som kinase-inhibitorer
DK3681885T3 (da) Tetrahydro-imidazo-quinolinsammensætninger som cbp/p300-inhibitorer
DK3324977T3 (da) Benzodiazepinderivater som rsv-inhibitorer
DK3461821T3 (da) Indolcarboxamidforbindelser, der er brugbar som kinasehæmmere
DK3190113T3 (da) Pyrrolopyrimidinforbindelser anvendt som tlr7-agonist
DK3582780T3 (da) Aminopyrimidinforbindelser, der er anvendelige som SSAO-inhibitorer
DK3294713T5 (da) Substituerede tetrahydroquinolinonforbindelser som ror-gamma-modulatorer
DK3580220T3 (da) Aminotriazolpyridiner som kinasehæmmere
DK3768674T3 (da) Aminopyrimidinderivater som ctps1-hæmmere
DK3762368T3 (da) Aminopyrazindiolforbindelser som pi3k-y-inhibitorer
DK3235819T3 (da) Pyrrolopyrimidinforbindelser, der er anvendelige som JAK-inhibitorer